GPhA Welcomes House Bill Exempting Generic Drug User Free Act Fees From Sequestration

Published Online: Monday, July 22, 2013
Follow Pharmacy_Times:
PRESS RELEASE

Washington, DC, July 22, 2013 -- The Generic Pharmaceutical Association (GPhA) applauds the bipartisan introduction of the FDA Safety Over Sequestration (SOS) Act (H.R. 2725) in the House of Representatives. This legislation would exempt FDA user fees, including those provided by generic manufacturers, from sequestration, the automatic federal budget cuts that went into effect in March 2013.

“One year ago, President Obama signed into law the Generic Drug User Fee Act (GDUFA),” said Ralph G. Neas, President and CEO of the Generic Pharmaceutical Association. “A landmark achievement for the generic industry, GDUFA authorizes the FDA to use private-industry-funded payments to reduce the backlog of generic drug applications, enhance safety, expedite access and promote transparency for high-quality and affordable generic drugs. All of these outcomes are at risk if user fees are subject to sequestration.

We commend the sponsors of the FDA SOS Act, Rep. Leonard Lance (R-NJ), Rep. Anna Eshoo (D-CA), Rep. Doris Matsui (D-CA), and Rep. Mike Rogers (R-MI),” continued Neas, “for recognizing that privately-funded user fees should be exempt from sequestration, and instead used to eliminate avoidable financial strain on the FDA. This vital measure would help the agency effectively carry out its mission.” GPhA joins AdvaMed, PhRMA and other industry trade groups in supporting the bill, which will improve timely access to safe and effective medicines and medical devices for all Americans.
Related Articles
“The Generic Pharmaceutical Association (GPhA) is deeply disappointed in today’s 21st Century Cures discussion draft. While we appreciate that it is a draft, in its current form, the bill would upset the important balance between creating competition and encouraging innovation in the pharmaceutical marketplace, putting savings at risk and limiting access to affordable medicines for millions of American patients.
The Generic Pharmaceutical Association announced today that Ralph G. Neas, President and CEO, would be stepping down from his position in the fall of 2015.
The Generic Pharmaceutical Association and its members congratulate Kathleen “Cook” Uhl, M.D. on her selection as permanent director of the Office of Generic Drugs.
GPhA applauds the new findings of the Senate Special Committee on Aging and welcomes further conversation on increasing generic drug utilization in government programs, particularly Medicare Part D.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$